Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma

Condition:   Thrombocytopenia Intervention:   Drug: Avatrombopag Sponsor:   Shanghai Zhongshan Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Cell Mol Biol (Noisy-le-grand). 2021 Aug 31;67(2):109-113. doi: 10.14715/cmb/2021.67.2.16.ABSTRACTTo investigate the first-line treatment of recurrent Nasopharyngeal Carcinoma treprimcab combined with chemotherapy. From January 2019 to January 2020, 48 patients with recurrent nasopharyngeal Carcinoma (RNPC) were treated in our hospital. According to the method of the random number, 24 patients were divided into the combined group and the Control Group. The patients in the combined group were given the Combined Treatment of triptolide and chemotherapy. While the Control Group only received chemotherapy. The therapeutic effe...
Source: Cellular and Molecular Biology - Category: Molecular Biology Authors: Source Type: research
This article explores the interaction between HBV infection and platelets, providing a theoretical basis for clinical treatment of thrombocytopenia and severe hemorrhage caused by HBV infection.PMID:34806523 | DOI:10.1080/09537104.2021.2002836
Source: Platelets - Category: Hematology Authors: Source Type: research
CONCLUSIONS: Marker-less SBRT for HCC achieved favorable local control that fulfilled the threshold. This result suggests that marker-less SBRT with appropriate settings is a feasible treatment strategy.PMID:34788194 | DOI:10.1080/0284186X.2021.2001566
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Source Type: research
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline dur...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Research | Thrombocytopenia